Literature DB >> 6260844

Interactions of agonists and antagonists with beta-adrenergic receptors on intact L6 muscle cells.

R N Pittman, P B Molinoff.   

Abstract

A binding assay has been developed to characterize beta-adrenergic receptors on intact L6 muscle cells. The affinity of beta-adrenergic receptors for the radioligand iodohydroxybenzylpindolol (IHYP) was the same in membrane preparations and in intact cells when determined by either equilibrium binding or kinetic analysis. The number of specific IHYP binding sites per cell was approximately the same on intact cells as on membranes. The pharmacological properties of antagonists indicated that the receptors on intact cells were identical to those on membranes. However, the beta-adrenergic receptors on intact cells had a 100-400 fold lower affinity at equilibrium for the agonist isoproterenol than did beta-adrenergic receptors on membranes. This low affinity of the receptor for agonists as measured by inhibition of radioligand binding in intact cells has also been observed in C6 (2) and S49 (3) cells. Our results suggest that beta receptors on intact cells after a 1 minute incubation was similar to the KD value for isoproterenol measured in membranes at equilibrium in the presence of GTP. After 1-2 minutes of exposure to a low concentration of agonist, binding of IHYP was no longer inhibited. These results suggest that agonists rapidly convert the beta receptors on intact cells to a state which has a low affinity for agonists. The affinity of the receptor for antagonists did not change during the incubation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6260844

Source DB:  PubMed          Journal:  J Cyclic Nucleotide Res        ISSN: 0095-1544


  12 in total

1.  Modulation of beta-receptors as adult and neonatal cardiac myocytes progress into culture.

Authors:  E Lundgren; L Terracio; D O Allen; T K Borg
Journal:  In Vitro Cell Dev Biol       Date:  1988-01

Review 2.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

3.  High-affinity binding of agonists to beta-adrenergic receptors on intact cells.

Authors:  M L Toews; T K Harden; J P Perkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

Review 4.  Beta-adrenergic receptor-coupled adenylate cyclase. Biochemical mechanisms of regulation.

Authors:  D R Sibley; R J Lefkowitz
Journal:  Mol Neurobiol       Date:  1987 Spring-Summer       Impact factor: 5.590

5.  Beta-adrenergic receptor properties of a pulmonary alveolar type II cell preparation from the adult rat.

Authors:  L G Jones; M E Gray; A J Wood; V S LeQuire
Journal:  Lung       Date:  1987       Impact factor: 2.584

6.  Genetic analysis of beta-adrenergic receptor internalization and down-regulation.

Authors:  L C Mahan; A M Koachman; P A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

7.  Plasma catecholamine modulation of alpha 2 adrenoreceptor agonist affinity and sensitivity in normotensive and hypertensive human platelets.

Authors:  A S Hollister; J Onrot; S Lonce; J H Nadeau; D Robertson
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  Competitive and non-competitive interactions between specific ligands and beta-adrenoceptors in living cardiac cells.

Authors:  H Porzig; C Becker; H Reuter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-11       Impact factor: 3.000

9.  Recovery of beta-adrenoceptors and cyclic AMP response after long term treatment of intact heart cells with beta-blockers.

Authors:  C Becker; H Porzig
Journal:  Br J Pharmacol       Date:  1984-07       Impact factor: 8.739

10.  Somatostatin alters beta-adrenergic receptor-effector coupling in cultured rat astrocytes.

Authors:  D L Niehoff; A W Mudge
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.